Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives.
Compound 5a shows strong potential as a broad-spectrum antibacterial agent with low resistance risk, but further research is needed to confirm its efficacy in clinical settings.
Where it sits
this study against the rest of the frag 176-191 corpusSummary and findings
This study focused on the design and synthesis of pyrroloquinazoline diamine derivatives to address antimicrobial resistance. Compound 5a was identified as having an IC50 of 0.92 nM for dihydrofolate reductase inhibition and demonstrated broad-spectrum antibacterial activity with MIC values as low as 0.5 μg/mL. The study highlights the potential of 5a in combating bacterial infections, though no therapeutic claims are made.
Abstract
To combat antimicrobial resistance (AMR), a novel series of pyrrolo[3,2-<i>f</i>]quinazoline-diamine (PQD) derivatives (<b>5a-5z</b>) featuring a flexible benzyl-oxo-benzyl side chain were designed and synthesised via structural optimisation of lead compound IRS-16. All compounds exhibited potent dihydrofolate reductase (DHFR) inhibition. Compound <b>5a</b> was most notable, showing exceptional enzymatic inhibition (IC<sub>50</sub> = 0.92 nM), surpassing both IRS-16 and trimethoprim. <b>5a</b> demonstrated broad-spectrum antibacterial activity against Gram-positive (e.g., <i>E. faecalis</i>) and Gram-negative strains (e.g., <i>E. coli</i>), as well as clinical isolates of <i>S. aureus, K. pneumoniae</i>, and uropathogenic <i>E. coli</i> (UPEC), with MIC values as low as 0.5 μg/mL. It displayed rapid bactericidal action, low resistance propensity, and inhibited biofilm formation by >90% at 0.5 μg/mL. Additional mechanisms included disruption of bacterial membrane integrity, causing leakage of cellular contents. These results identify <b>5a</b> as a promising lead for developing novel, broad-spectrum DHFR inhibitors with a low resistance risk.
Background
The study addresses the growing concern of antimicrobial resistance (AMR) and the need for new antibacterial agents. Prior research has established the importance of dihydrofolate reductase (DHFR) as a target for antibiotic development. This study is significant as it presents a novel series of compounds that may offer enhanced efficacy against resistant bacterial strains.
Methods
The study involved the design and synthesis of pyrroloquinazoline-diamine derivatives, specifically compounds 5a-5z. The primary outcome measure was the IC50 value for DHFR inhibition, while secondary measures included minimum inhibitory concentration (MIC) and biofilm formation inhibition. Not reported in abstract.
Results
The primary endpoint showed that compound 5a had an IC50 of 0.92 nM for DHFR inhibition. Additionally, it exhibited MIC values as low as 0.5 μg/mL against various bacterial strains, indicating potent antibacterial activity. The compound also demonstrated >90% inhibition of biofilm formation at the same concentration.
Interpretation
The findings suggest that compound 5a is a promising candidate for further development as a broad-spectrum antibacterial agent. While the IC50 value is statistically significant, the clinical relevance remains uncertain without human data. Limitations such as the absence of in vivo data and potential confounding factors in the study design should be considered when interpreting these results.
Key findings
- IC50 = 0.92 nM for compound 5a against dihydrofolate reductase.
- MIC values as low as 0.5 μg/mL for compound 5a against various bacterial strains.
- >90% inhibition of biofilm formation at 0.5 μg/mL for compound 5a.
Limitations
- Not reported in abstract.
- In vitro study, no human data provided.
- Potentially limited by small sample size of tested compounds.